Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Dec 16, 2016	Aberman Michael S SVP Strategy Investor Relation	SVP Strategy Investor Relation	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	21,675	--	21,675
Dec 16, 2015	Aberman Michael S SVP Strategy Investor Relation	SVP Strategy Investor Relation	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	25,500	--	25,500
Dec 16, 2014	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	30,000	--	30,000
Dec 13, 2013	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	30,000	--	30,000
Dec 14, 2012	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	35,000	--	35,000
Dec 16, 2011	Aberman Michael S VP Strategy and Investor Relat	VP Strategy and Investor Relat	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	35,000	--	35,000
Dec 14, 2010	Aberman Michael S VP, Strat and Invest Relations	VP, Strat and Invest Relations	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	30,000	--	30,000
Mar 22, 2010	Aberman Michael S VP, Strat and Invest Relations	VP, Strat and Invest Relations	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	10,000	--	10,000
Mar 22, 2010	Aberman Michael S VP, Strat and Invest Relations	VP, Strat and Invest Relations	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	20,830	--	20,830
Mar 22, 2010	Aberman Michael S VP, Strat and Invest Relations	VP, Strat and Invest Relations	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	79,170	--	79,170

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media